La tarification au prix de référence : quel impact sur le marché pharmaceutique ?
Increases in national pharmaceutical spending have led governments to adopt new measures aimed at promoting price competition. One such approach to regulate the pharmaceutical market is reference pricing. A reference price system categorises products into groups so that the reference price is the maximum reimbursement of the third party payer for all products in that group. Using a vertical product differentiation model, we deduce that the reference price system can generate a drug price cut. However the impact on public expenditures is uncertain.
Volume (Year): 119 (2009)
Issue (Month): 5 ()
|Contact details of provider:|| Web page: http://www.cairn.info/revue-d-economie-politique.htm|
When requesting a correction, please mention this item's handle: RePEc:cai:repdal:redp_195_0795. See general information about how to correct material in RePEc.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (Jean-Baptiste de Vathaire)
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
If references are entirely missing, you can add them using this form.
If the full references list an item that is present in RePEc, but the system did not link to it, you can help with this form.
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your profile, as there may be some citations waiting for confirmation.
Please note that corrections may take a couple of weeks to filter through the various RePEc services.